Yang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yang Chen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Zongyao Hao
Department of Urology The First Affiliated Hospital of Anhui Medical University Hefei Anhui China
10 shared publications - Bingbing Hou
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
6 shared publications Yuexian Xu
Department of Emergency Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, PR China
5 shared publicationsHu Liang
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Institute of Urology, Anhui Medical University, Hefei, China; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, China
4 shared publicationsXike Mao
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Institute of Urology, Anhui Medical University, Hefei, China; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, China
4 shared publicationsZhenyu Song
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Institute of Urology, Anhui Medical University, Hefei, China; Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, China
4 shared publications
Latest Publications
- 24 December 2025
- Published by Springer Nature in Urolithiasis
- Vol. 54 (1) , 20
GGT1 protects against calcium oxalate crystal-induced renal tubular epithelial cell injury by targeting GCLC
- 24 December 2025
- Published by Springer Nature in Urolithiasis
- Vol. 54 (1) , 20
GGT1 protects against calcium oxalate crystal-induced renal tubular epithelial cell injury by targeting GCLC
- Open Access
- 11 December 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 309, 119557
Lead exposure aggravates calcium oxalate crystal-induced renal injury and inflammation by upregulating IRF7 and promoting M1 macrophage polarization
- 11 December 2025
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 309, 119557
Open AccessLead exposure aggravates calcium oxalate crystal-induced renal injury and inflammation by upregulating IRF7 and promoting M1 macrophage polarization
- Open Access
- 7 March 2025
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 1-8
The ratio of perirenal fat thickness to renal parenchymal thickness, a novel indicator of fat accumulation associated with kidney stones
Metabolic syndrome, identified by increased visceral fat accumulation, is notably linked to a heightened risk of nephrolithiasis. Despite this, the influence of the perirenal fat thickness relative to renal parenchymal thickness on kidney stones (KS) development remains ambiguous. This study investigated the clinical characteristics of perirenal fat on both the left and right sides and explored the association between the aforementioned ratio and KS. The study enrolled 161 participants who underwent computed tomography (CT) scans. In this study, kidneys were segregated into two categories based on the presence of stones: stone-bearing and non-stone-bearing for both the left and right kidneys. Perirenal fat parameters were extracted from the imaging workstation database. Both univariate and multivariate logistic regression analyses were conducted to explore the correlation between metrics related to perirenal fat and the occurrence of KS. Among the 161 participants, significant variations in perirenal fat were observed between the left and right kidneys, as well as between genders. Subsequent to adjustments for several confounding variables, the multivariable logistic regression model demonstrated a significant correlation between the ratio of perirenal fat thickness to renal parenchymal thickness and stone bearing kidney (P < 0.001). The ratio of perirenal fat thickness to renal parenchymal thickness was significantly correlated with kidney stones.
- 7 March 2025
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 1-8
Open AccessThe ratio of perirenal fat thickness to renal parenchymal thickness, a novel indicator of fat accumulation associated with kidney stones
Metabolic syndrome, identified by increased visceral fat accumulation, is notably linked to a heightened risk of nephrolithiasis. Despite this, the influence of the perirenal fat thickness relative to renal parenchymal thickness on kidney stones (KS) development remains ambiguous. This study investigated the clinical characteristics of perirenal fat on both the left and right sides and explored the association between the aforementioned ratio and KS. The study enrolled 161 participants who underwent computed tomography (CT) scans. In this study, kidneys were segregated into two categories based on the presence of stones: stone-bearing and non-stone-bearing for both the left and right kidneys. Perirenal fat parameters were extracted from the imaging workstation database. Both univariate and multivariate logistic regression analyses were conducted to explore the correlation between metrics related to perirenal fat and the occurrence of KS. Among the 161 participants, significant variations in perirenal fat were observed between the left and right kidneys, as well as between genders. Subsequent to adjustments for several confounding variables, the multivariable logistic regression model demonstrated a significant correlation between the ratio of perirenal fat thickness to renal parenchymal thickness and stone bearing kidney (P < 0.001). The ratio of perirenal fat thickness to renal parenchymal thickness was significantly correlated with kidney stones.
- 18 February 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 150, 114302
SIRT6 attenuates calcium oxalate Nephrocalcinosis-induced renal inflammation and oxidative injury via activating NRF2 signaling
- 18 February 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 150, 114302
SIRT6 attenuates calcium oxalate Nephrocalcinosis-induced renal inflammation and oxidative injury via activating NRF2 signaling
- 12 February 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 150, 114250
Umbelliferone attenuates calcium oxalate crystal-induced renal injury and inflammation by attenuating autophagy through the PI3K/AKT pathway
- 12 February 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 150, 114250
Umbelliferone attenuates calcium oxalate crystal-induced renal injury and inflammation by attenuating autophagy through the PI3K/AKT pathway
- 19 December 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 146, 113864
The SIRT6 allosteric activator MDL-800 suppresses calcium oxalate nephrocalcinosis by alleviating inflammatory and renal damage
- 19 December 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 146, 113864
The SIRT6 allosteric activator MDL-800 suppresses calcium oxalate nephrocalcinosis by alleviating inflammatory and renal damage
- 12 December 2024
- Published by Springer Nature in Urolithiasis
- Vol. 53 (1) , 1-14
Based on network pharmacology, the mechanism of Dioscin in alleviating renal tubular epithelial cell injury induced by calcium oxalate crystals was explored
The commencement of kidney stone formation involves a crucial initial phase characterized by injury to renal tubular cells caused by calcium oxalate (CaOx). Dioscin (Dio) has been acknowledged for its potent anti-inflammation and anti-apoptotic properties; nevertheless, the impact and underlying Investigation into the molecular basis underlying the action of Dioscin in mitigating inflammation and apoptotic induced by exposure to calcium oxalate crystals in renal tissues remain unexplored. To comprehend the precise mechanism of Dioscin in the treatment of crystalline nephropathy, we conducted experiments utilizing a murine model of CaOx crystal deposition, induced by intraperitoneal administration of glyoxylate. An in vitro model was constructed using HK-2 cells exposed to calcium oxalate monohydrate (COM). To evaluate the effect of Dioscin on calcium oxalate crystal deposition by ROS assay, Western blotting, immunohistochemistry, Periodic Acid-Schiff staining (PAS) staining, hematoxylin–eosin (H&E) staining. Using network pharmacology and molecular docking methods, we explored the molecular mechanism of Dioscin in the treatment of CaOx-induced renal tubular epithelial cell injury. Subsequently, we conducted experiments to verify our findings. We observed a significant protective effect of Dioscin treatment against kidney oxidative stress and inflammation induced by CaOx. Then we predicted through network pharmacology that Dioscin exerts its anti-apoptotic effect through the NF-kappa B signaling pathway. Then we verified in vitro and in vivo that administration of Dioscin can alleviate the elevation of TLR4 and activation of the NF-kappa B signaling pathway induced by calcium oxalate, as well as attenuate renal apoptosis. Instead, the beneficial impact of this protection of Dioscin was reversed after overexpression of the TLR4. Dioscin has the potential to alleviate the activation of the NF-kappa B signaling pathway through TLR4, thereby exerting anti-inflammatory and anti-apoptotic effects. This study provides new ideas for the prevention and treatment of kidney stones.
- 12 December 2024
- Published by Springer Nature in Urolithiasis
- Vol. 53 (1) , 1-14
Based on network pharmacology, the mechanism of Dioscin in alleviating renal tubular epithelial cell injury induced by calcium oxalate crystals was explored
The commencement of kidney stone formation involves a crucial initial phase characterized by injury to renal tubular cells caused by calcium oxalate (CaOx). Dioscin (Dio) has been acknowledged for its potent anti-inflammation and anti-apoptotic properties; nevertheless, the impact and underlying Investigation into the molecular basis underlying the action of Dioscin in mitigating inflammation and apoptotic induced by exposure to calcium oxalate crystals in renal tissues remain unexplored. To comprehend the precise mechanism of Dioscin in the treatment of crystalline nephropathy, we conducted experiments utilizing a murine model of CaOx crystal deposition, induced by intraperitoneal administration of glyoxylate. An in vitro model was constructed using HK-2 cells exposed to calcium oxalate monohydrate (COM). To evaluate the effect of Dioscin on calcium oxalate crystal deposition by ROS assay, Western blotting, immunohistochemistry, Periodic Acid-Schiff staining (PAS) staining, hematoxylin–eosin (H&E) staining. Using network pharmacology and molecular docking methods, we explored the molecular mechanism of Dioscin in the treatment of CaOx-induced renal tubular epithelial cell injury. Subsequently, we conducted experiments to verify our findings. We observed a significant protective effect of Dioscin treatment against kidney oxidative stress and inflammation induced by CaOx. Then we predicted through network pharmacology that Dioscin exerts its anti-apoptotic effect through the NF-kappa B signaling pathway. Then we verified in vitro and in vivo that administration of Dioscin can alleviate the elevation of TLR4 and activation of the NF-kappa B signaling pathway induced by calcium oxalate, as well as attenuate renal apoptosis. Instead, the beneficial impact of this protection of Dioscin was reversed after overexpression of the TLR4. Dioscin has the potential to alleviate the activation of the NF-kappa B signaling pathway through TLR4, thereby exerting anti-inflammatory and anti-apoptotic effects. This study provides new ideas for the prevention and treatment of kidney stones.
- Open Access
- 27 October 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (20) , e70180
Puerarin alleviates apoptosis and inflammation in kidney stone cells via the PI3K/AKT pathway: Network pharmacology and experimental verification
Puerarin(PUE), an isoflavonoid extracted from Pueraria root, has anti‐apoptotic effects. The objective of this research is to examine the impact of PUE on renal apoptosis and inflammation resulting from renal calculi and to elucidate its mechanism. The approach of network pharmacology and molecular docking was employed to discover potential targets and pathways of PUE. An animal model of calcium oxalate crystal deposition by intraperitoneal injection of glyoxylate and a model of COM‐induced human renal tubular epithelial cells (HK2) were used to investigate the pharmacological mechanisms of PUE against apoptosis and inflammation. We used haematoxylin–eosin (H&E) and Periodic Acid‐Schiff staining (PAS) to assess the effect of PUE on crystal deposition and damage. The mechanism of PUE was elucidated and validated using Western blotting, histology and immunohistochemical staining. Network pharmacology findings indicated that the PI3K/AKT pathway plays a crucial role in PUE. We experimentally demonstrate that PUE alleviated COM‐induced changes in apoptotic proteins, increased inflammatory indicators and changes in oxidative stress‐related indicators in HK2 cells by activating the PI3K/AKT pathway, reduced serum creatinine and urea nitrogen levels in mice caused by CaOx, alleviated crystal deposition and damage, and alleviated apoptosis, oxidative stress and inflammation. Puerarin attenuates renal apoptosis and inflammation caused by kidney stones through the PI3K/AKT pathway.
- 27 October 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (20) , e70180
Open AccessPuerarin alleviates apoptosis and inflammation in kidney stone cells via the PI3K/AKT pathway: Network pharmacology and experimental verification
Puerarin(PUE), an isoflavonoid extracted from Pueraria root, has anti‐apoptotic effects. The objective of this research is to examine the impact of PUE on renal apoptosis and inflammation resulting from renal calculi and to elucidate its mechanism. The approach of network pharmacology and molecular docking was employed to discover potential targets and pathways of PUE. An animal model of calcium oxalate crystal deposition by intraperitoneal injection of glyoxylate and a model of COM‐induced human renal tubular epithelial cells (HK2) were used to investigate the pharmacological mechanisms of PUE against apoptosis and inflammation. We used haematoxylin–eosin (H&E) and Periodic Acid‐Schiff staining (PAS) to assess the effect of PUE on crystal deposition and damage. The mechanism of PUE was elucidated and validated using Western blotting, histology and immunohistochemical staining. Network pharmacology findings indicated that the PI3K/AKT pathway plays a crucial role in PUE. We experimentally demonstrate that PUE alleviated COM‐induced changes in apoptotic proteins, increased inflammatory indicators and changes in oxidative stress‐related indicators in HK2 cells by activating the PI3K/AKT pathway, reduced serum creatinine and urea nitrogen levels in mice caused by CaOx, alleviated crystal deposition and damage, and alleviated apoptosis, oxidative stress and inflammation. Puerarin attenuates renal apoptosis and inflammation caused by kidney stones through the PI3K/AKT pathway.
- 16 October 2024
- Published by Springer Nature in Urolithiasis
- Vol. 52 (1) , 1-6
Predictive factors of stone-free rate and complications in patients with proximal impacted ureteral stones undergoing percutaneous nephrolithotomy: based on a new scoring standard
To evaluate the predictive factors affecting the stone-free rate (SFR) and complications of percutaneous nephrolithotomy (PCN) in the treatment of proximal impacted ureteral stones (PIUS) based on a new scoring standard. The data of 90 patients with PIUS were collected in this retrospective study between January 2015 and June 2023. Univariate and multivariate logistic regression analyses were used to determine factors affecting treatment outcome in terms of SFR and complications. The scoring standard for patients with PIUS was developed based on the univariate logistic regression analyses. In the univariate analysis, stone density (P = 0.015), and stone diameter (P = 0.032) significantly were associated with lower SFR. And degree of hydronephrosis (P = 0.014), Preoperative infection (P = 0.002), and history of lithotripsy (P = 0.045) were associated with occurrence of complications. Multivariate analysis indicated that stone density (P = 0.020), and stone diameter (P < 0.001) were associated with lower SFR; independent risk factors for development of complications were history of lithotripsy (P = 0.024), and preoperative infection (P < 0.001). Additionally, score ≥ 3 was the independent risk factor for both SFR (P < 0.001) and complication rate (P < 0.001). Subgroup analysis shown that there were statistically significant differences between the two groups in terms of stone-free rate (P = 0.032) and complications (P = 0.015). According to the findings of this study, the stone score ≥ 3 was determined as a critical predictive factor of SFR and complications in PIUS patients undergoing PCN based on a new scoring standard. Additionally, PCN has high initial SFR and low complications when dealing with score < 3 PIUS.
- 16 October 2024
- Published by Springer Nature in Urolithiasis
- Vol. 52 (1) , 1-6
Predictive factors of stone-free rate and complications in patients with proximal impacted ureteral stones undergoing percutaneous nephrolithotomy: based on a new scoring standard
To evaluate the predictive factors affecting the stone-free rate (SFR) and complications of percutaneous nephrolithotomy (PCN) in the treatment of proximal impacted ureteral stones (PIUS) based on a new scoring standard. The data of 90 patients with PIUS were collected in this retrospective study between January 2015 and June 2023. Univariate and multivariate logistic regression analyses were used to determine factors affecting treatment outcome in terms of SFR and complications. The scoring standard for patients with PIUS was developed based on the univariate logistic regression analyses. In the univariate analysis, stone density (P = 0.015), and stone diameter (P = 0.032) significantly were associated with lower SFR. And degree of hydronephrosis (P = 0.014), Preoperative infection (P = 0.002), and history of lithotripsy (P = 0.045) were associated with occurrence of complications. Multivariate analysis indicated that stone density (P = 0.020), and stone diameter (P < 0.001) were associated with lower SFR; independent risk factors for development of complications were history of lithotripsy (P = 0.024), and preoperative infection (P < 0.001). Additionally, score ≥ 3 was the independent risk factor for both SFR (P < 0.001) and complication rate (P < 0.001). Subgroup analysis shown that there were statistically significant differences between the two groups in terms of stone-free rate (P = 0.032) and complications (P = 0.015). According to the findings of this study, the stone score ≥ 3 was determined as a critical predictive factor of SFR and complications in PIUS patients undergoing PCN based on a new scoring standard. Additionally, PCN has high initial SFR and low complications when dealing with score < 3 PIUS.
- 20 February 2024
- Published by Springer Nature in Urolithiasis
- Vol. 52 (1) , 1-9
Molecular mechanism of Rhizoma Polygonati in the treatment of nephrolithiasis: network pharmacology analysis and in vivo experimental verification
Rhizoma Polygonati (RP) is the dried rhizome of the liliaceous plant. It has anti-inflammatory and anti-apoptosis effects. But its role in kidney stones has not been studied. The purpose of this study was to verify the effect of RP in the treatment of nephrolithiasis through network pharmacological analysis and in vivo experiments. The active compounds and protein targets of RP, as well as the potential targets of the nephrolithiasis were searched from the database. The protein–protein interaction (PPI) network diagram and the drug–compounds–targets–disease network were constructed. The enrichment analysis was performed by Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, the effect of RP on the prevention and treatment of nephrolithiasis was experimentally validated in vivo. Animal experiments showed that RP ameliorates renal function and reduced crystal deposition in a mouse model. It may act through anti-inflammation and anti-apoptosis. Our study showed that RP could prevent and treat nephrolithiasis by inhibiting apoptosis and inflammation, which provided a new efficacy and clinical application for RP.
- 20 February 2024
- Published by Springer Nature in Urolithiasis
- Vol. 52 (1) , 1-9
Molecular mechanism of Rhizoma Polygonati in the treatment of nephrolithiasis: network pharmacology analysis and in vivo experimental verification
Rhizoma Polygonati (RP) is the dried rhizome of the liliaceous plant. It has anti-inflammatory and anti-apoptosis effects. But its role in kidney stones has not been studied. The purpose of this study was to verify the effect of RP in the treatment of nephrolithiasis through network pharmacological analysis and in vivo experiments. The active compounds and protein targets of RP, as well as the potential targets of the nephrolithiasis were searched from the database. The protein–protein interaction (PPI) network diagram and the drug–compounds–targets–disease network were constructed. The enrichment analysis was performed by Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG). Subsequently, the effect of RP on the prevention and treatment of nephrolithiasis was experimentally validated in vivo. Animal experiments showed that RP ameliorates renal function and reduced crystal deposition in a mouse model. It may act through anti-inflammation and anti-apoptosis. Our study showed that RP could prevent and treat nephrolithiasis by inhibiting apoptosis and inflammation, which provided a new efficacy and clinical application for RP.